Spasticity, Muscle Clinical Trial
Official title:
A Phase IIb Study of the Safety and Efficacy of Nabiximols in Subjects With Spasticity Due to Neuromyelitis Optica Spectrum Disorders: A Double-blind, Randomized, Placebo-Controlled, Crossover Study
The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD. The main question it aims to answer is whether treatment with nabiximols improves patient-reported spasticity ratings compared to treatment with a placebo. This trial will also answer whether nabiximols impact pain, spasm frequency, mood, walking ability, and sleep. Participants will be mailed the treatments and placebo treatments, and will be asked to complete study visits and questionnaires remotely. There is also an optional sub-study that involves in-person visits with ultrasound imaging and in-person neurologic exams.
Patients with NMOSD often have medication-resistant and severe spasticity due to longitudinally extensive spinal cord lesions. Existing treatments are limited by their efficacy and tolerability. Cannabinoids have been shown to quantitatively improve spasticity in mouse models of neuroinflammation, and nabiximols, a cannabinoid-based oromucosal spray, have demonstrated efficacy for medication-resistant spasticity in multiple sclerosis. However, no studies have as yet explored the use of nabiximols specifically in NMOSD, and there is a significant unmet need for new symptomatic treatments in this patient population. The goal of this study is to evaluate the safety and efficacy of nabiximols spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and seronegative NMOSD. This study is designed as a phase IIb, single-site, double-blind, randomized, placebo-controlled 2x2 crossover clinical trial, with a 2-week washout period between treatment periods. After randomization, each participant enters into Period 1, which begins with a 2-week dose escalation period with a pre-defined dose escalation scheme, followed by a 4-week stable treatment period. After completion of Period 1, all participants have a 2-week washout period and then enter Period 2, where they again complete a 2-week dose escalation period and 4-week constant treatment period. The patient-reported 0-10 numeric rating scale for spasticity (NRS-S) is the primary outcome measure. All key study procedures are performed virtually, including a weekly electronic study diary, additional weekly surveys, and 8 virtual video-based study visits including a screening visit and safety follow up visit. Additional optional in-person assessments of spasticity (neurologic exam, modified Ashworth Scale and muscle ultrasound elastography) will be performed for a selection of local participants. In total, the study has a 20-week duration per participant, from the screening visit to the final study completion for safety follow-up visit, including 12 weeks of on-treatment time. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT03908580 -
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity
|
Phase 4 | |
Not yet recruiting |
NCT04550793 -
Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
|
||
Recruiting |
NCT05432999 -
Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury
|
N/A | |
Completed |
NCT05687097 -
Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
|
||
Active, not recruiting |
NCT05562453 -
Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain
|
N/A | |
Recruiting |
NCT06214975 -
EXOPULSE Mollii Suit, Motor Function & Stroke (EXOSTROKE 2)
|
N/A | |
Recruiting |
NCT05464160 -
Focal Muscular Vibration in Patients With Severe Acquired Brain Injury
|
N/A | |
Completed |
NCT04130295 -
Influence of Wearable Intensive Nerve Stimulation on Spasticity and Function in Persons With Spinal Cord Injury
|
N/A | |
Recruiting |
NCT06070233 -
Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy
|
N/A | |
Completed |
NCT03747900 -
Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity
|
N/A | |
Completed |
NCT03307135 -
Medical Spastic Patient Machine Interface MSPMI : Biomechanical and Electrophysiological Assessment of the Triceps Surae Spasticity
|
N/A | |
Recruiting |
NCT05070780 -
Neurophysiological Evaluation of Muscle Tone
|
||
Recruiting |
NCT04620707 -
RGS@Home: Personalized 24/7 Home Care Post-stroke
|
N/A | |
Recruiting |
NCT06109129 -
Investıgatıon Of The Effectıveness Of The Mollıı Suıt In Chıldren Wıth Ambulatory Cerebral Palsy
|
N/A | |
Enrolling by invitation |
NCT05598736 -
Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain
|
N/A | |
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Active, not recruiting |
NCT05626790 -
Effects of PNF and Static Stretching on Architecture and Viscoelastic Properties of Hemiplegic Elbow
|
N/A | |
Recruiting |
NCT04904016 -
Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity
|
N/A | |
Withdrawn |
NCT05887479 -
The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity
|
Phase 4 |